Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anthem Biosciences Ltd. (ANTHEM.NS)
Bengaluru, IN
Anthem Biosciences Ltd. operates as a technology-driven organization specializing in contract research, development, and manufacturing (CRDMO). The company's activities are organized into two primary divisions: CRDMO services and the production of Specialty Ingredients. Through its CRDMO segment, Anthem Biosciences offers comprehensive, full-lifecycle support for both novel chemical and biological entities. This support spans the entire development pipeline, from initial target identification and concept generation, through preclinical evaluation, the creation of development batches for all three phases of clinical trials, and ultimately, commercial-scale manufacturing. Their expertise covers a wide array of advanced therapeutic areas, including RNA-based therapies, antibody-drug conjugates, peptides, oligonucleotides, lipids, biologics, and biotherapeutics. They also employ specialized processes such as fermentation, biosynthesis, biotransformation, and flow chemistry. In its Specialty Ingredients division, Anthem Biosciences manufactures and supplies intricate, fermentation-derived active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2. The company's portfolio also encompasses microbial and mammalian biosimilars, a diverse range of probiotics (such as various species of bacillus, lactobacillus, bifidobacterium, streptococcus, and saccharomyces boulardii), and enzymes. Additionally, they produce key peptides like semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide, alongside nutritional actives, vitamin analogues, and other APIs. The company was established in Bengaluru, India, in 2006.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.36% | -2.81% | +0.36% | +8.46% | +19.66% | +16.73% | +4.05% | +4.05% | +4.05% | +4.05% | +4.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+15.2% ★ Q1'26: +26.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+29.7% ★ Q1'26: +125.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+28.2% ★ Q1'26: +45.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+32.9% ★ Q1'26: +37.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+23.3% ★ Q1'26: +28.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.06× ★ Q1'26: 0.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2026 7 Rev. Ana. 5 EPS Ana. |
Mar 2027 7 Rev. Ana. 5 EPS Ana. |
Mar 2028 7 Rev. Ana. 5 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|
| Revenue |
21.27B
20.81B – 21.52B
|
25.72B
25.33B – 26.55B
+20.9% YoY
|
30.97B
29.90B – 33.42B
+20.4% YoY
|
36.12B
35.19B – 38.22B
+16.6% YoY
|
| EBITDA |
8.54B
8.35B – 8.64B
|
10.32B
10.17B – 10.65B
+20.9% YoY
|
12.43B
12.00B – 13.41B
+20.4% YoY
|
14.49B
14.12B – 15.33B
+16.6% YoY
|
| EBIT |
7.35B
7.19B – 7.44B
|
8.88B
8.75B – 9.17B
+20.9% YoY
|
10.70B
10.33B – 11.55B
+20.4% YoY
|
12.48B
12.16B – 13.20B
+16.6% YoY
|
| Net Income |
6.23B
5.92B – 6.55B
|
7.53B
7.37B – 7.68B
+20.7% YoY
|
8.82B
8.77B – 9.41B
+17.2% YoY
|
11.21B
11.08B – 11.57B
+27.2% YoY
|
| SGA |
1.06B
1.04B – 1.07B
|
1.28B
1.27B – 1.33B
+20.9% YoY
|
1.55B
1.49B – 1.67B
+20.4% YoY
|
1.80B
1.76B – 1.91B
+16.6% YoY
|
| EPS |
11.08
10.43 – 11.54
|
13.32
12.98 – 13.54
+20.3% YoY
|
16.14
15.46 – 16.58
+21.2% YoY
|
19.96
19.52 – 20.40
+23.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI India Small-Cap ETF SMIN | 0.19% | 1.40M | 0.74% |
| 2 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 178.2K | 0.55% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 96.5K | 0.74% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 92.6K | 0.72% |
| 5 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.01% | 3.02M | 0.18% |
| 6 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.01% | 123.7K | 0.18% |
| 7 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 158.7K | 0.28% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 8.9K | 0.35% |
| 9 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 6.7K | 0.58% |
| 10 | iShares Core MSCI Emerging Markets ETF IEMG | 0.00% | 2.80M | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ajay Bhardwaj | Founder, Chairman, MD & Chief Executive Officer | — | male |
| Divya Prasad | Company Secretary & Compliance Officer | — | female |
| Ganesh Sambasivam | Chief Scientific Officer & Executive Director | — | — |
| Ishaan Bhardwaj | Vice President | — | male |
| K. Ravindra Chandrappa | Co-Founder, Chief Operating Officer & Executive Director | — | male |
| Krishnan Ramakrishnan | General Counsel | — | male |
| Malay Jiban Barua | Vice President & Head of Operations of Specialty Ingredients | — | male |
| Mohammed Gawir Baig | Chief Financial Officer | — | male |
| Prakash Kariabettan | Vice President of Business Development (CDMO) | — | male |
| Rupesh N. Kinekar | Vice President of Marketing | — | male |
| Satish Sharma | Vice President of Sales | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANTHEM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
